Soaring revenue and an improving bottom line were the big stories for the Canadian marijuana producer in the first quarter.
News & Analysis: Emerald Health Therapeutics Inc
Production efficiency isn't a strong suit for these marijuana growers.
Subpar production efficiency and few provincial supply deals make both of these pot stocks avoidable.
After lagging other major growers, this pot stock notably upped its output.
Will this top-tier marijuana grower finally get some respect from Wall Street?
Wall Street's consensus price target for these marijuana stocks implies big gains.
This has been a big year for production and product line expansion, but it doesn't necessarily make this marijuana stock a buy.
There's more to investing in pot stocks than peak production estimates.
Pot stocks were blazing hot in August, with the top performer nearly tripling in value.
The closer we get to the green rush, the more red this pot stock seems to produce.